CRL Annual Cash & Cash Equivalents
$276.77 M
+$42.86 M+18.32%
30 December 2023
Summary:
As of January 21, 2025, CRL annual cash & cash equivalents is $276.77 million, with the most recent change of +$42.86 million (+18.32%) on December 30, 2023. During the last 3 years, it has risen by +$48.35 million (+21.17%). CRL annual cash & cash equivalents is now at all-time high.CRL Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRL Quarterly Cash And Cash Equivalents
$210.17 M
+$30.96 M+17.27%
28 September 2024
Summary:
As of January 21, 2025, CRL quarterly cash and cash equivalents is $210.17 million, with the most recent change of +$30.96 million (+17.27%) on September 28, 2024. Over the past year, it has dropped by -$66.60 million (-24.06%). CRL quarterly cash and cash equivalents is now -54.84% below its all-time high of $465.41 million, reached on March 27, 2021.CRL Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRL Cash And Cash Equivalents Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +18.3% | -24.1% |
3 y3 years | +21.2% | -24.1% |
5 y5 years | +41.6% | -24.1% |
CRL Cash And Cash Equivalents High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +18.3% | -35.7% | +33.7% |
5 y | 5-year | at high | +21.2% | -54.8% | +33.7% |
alltime | all time | at high | +1743.9% | -54.8% | +1038.6% |
Charles River Laboratories International Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $210.17 M(+17.3%) |
June 2024 | - | $179.21 M(-45.2%) |
Mar 2024 | - | $327.04 M(+18.2%) |
Dec 2023 | $276.77 M(+18.3%) | $276.77 M(+76.1%) |
Sept 2023 | - | $157.17 M(-21.6%) |
June 2023 | - | $200.44 M(-0.6%) |
Mar 2023 | - | $201.59 M(-13.8%) |
Dec 2022 | $233.91 M(-3.0%) | $233.91 M(+20.8%) |
Sept 2022 | - | $193.70 M(-3.3%) |
June 2022 | - | $200.32 M(-17.2%) |
Mar 2022 | - | $241.87 M(+0.3%) |
Dec 2021 | $241.21 M(+5.6%) | $241.21 M(+13.5%) |
Sept 2021 | - | $212.54 M(-4.7%) |
June 2021 | - | $222.97 M(-52.1%) |
Mar 2021 | - | $465.41 M(+103.7%) |
Dec 2020 | $228.42 M(-4.0%) | $228.42 M(-6.0%) |
Sept 2020 | - | $242.88 M(-39.6%) |
June 2020 | - | $402.02 M(+7.9%) |
Mar 2020 | - | $372.43 M(+56.5%) |
Dec 2019 | $238.01 M(+21.8%) | $238.01 M(+44.5%) |
Sept 2019 | - | $164.76 M(-17.9%) |
June 2019 | - | $200.59 M(+58.8%) |
Mar 2019 | - | $126.32 M(-35.4%) |
Dec 2018 | $195.44 M(+19.3%) | $195.44 M(+40.7%) |
Sept 2018 | - | $138.87 M(-27.8%) |
June 2018 | - | $192.30 M(+2.4%) |
Mar 2018 | - | $187.77 M(+14.6%) |
Dec 2017 | $163.79 M(+39.2%) | $163.79 M(+32.5%) |
Sept 2017 | - | $123.62 M(+6.1%) |
June 2017 | - | $116.47 M(-11.4%) |
Mar 2017 | - | $131.52 M(+11.8%) |
Dec 2016 | $117.63 M(-0.3%) | $117.63 M(+11.3%) |
Sept 2016 | - | $105.72 M(-31.6%) |
June 2016 | - | $154.59 M(-1.8%) |
Mar 2016 | - | $157.38 M(+33.4%) |
Dec 2015 | $117.95 M(-26.3%) | $117.95 M(+59.3%) |
Sept 2015 | - | $74.03 M(-50.9%) |
June 2015 | - | $150.81 M(-0.7%) |
Mar 2015 | - | $151.92 M(-5.1%) |
Dec 2014 | $160.02 M(+2.6%) | $160.02 M(+22.4%) |
Sept 2014 | - | $130.75 M(+11.7%) |
June 2014 | - | $117.01 M(-31.1%) |
Mar 2014 | - | $169.85 M(+8.9%) |
Dec 2013 | $155.93 M(+42.2%) | $155.93 M(+19.5%) |
Sept 2013 | - | $130.45 M(+14.9%) |
June 2013 | - | $113.52 M(+13.0%) |
Mar 2013 | - | $100.42 M(-8.4%) |
Dec 2012 | $109.69 M | $109.69 M(+31.8%) |
Sept 2012 | - | $83.22 M(+9.4%) |
June 2012 | - | $76.08 M(+24.7%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2012 | - | $61.03 M(-11.4%) |
Dec 2011 | $68.91 M(-61.5%) | $68.91 M(-15.2%) |
Sept 2011 | - | $81.22 M(-44.3%) |
June 2011 | - | $145.83 M(-8.1%) |
Mar 2011 | - | $158.75 M(-11.4%) |
Dec 2010 | $179.16 M(-1.9%) | $179.16 M(+30.4%) |
Sept 2010 | - | $137.43 M(-37.3%) |
June 2010 | - | $219.08 M(-1.4%) |
Mar 2010 | - | $222.20 M(+21.7%) |
Dec 2009 | $182.57 M(-25.0%) | $182.57 M(-5.0%) |
Sept 2009 | - | $192.20 M(+24.2%) |
June 2009 | - | $154.81 M(-9.1%) |
Mar 2009 | - | $170.23 M(-30.1%) |
Dec 2008 | $243.59 M(+8.0%) | $243.59 M(+14.4%) |
Sept 2008 | - | $212.85 M(-18.9%) |
June 2008 | - | $262.44 M(+9.4%) |
Mar 2008 | - | $239.88 M(+6.4%) |
Dec 2007 | $225.45 M(+28.5%) | $225.45 M(+22.9%) |
Sept 2007 | - | $183.50 M(+13.2%) |
June 2007 | - | $162.05 M(+18.7%) |
Mar 2007 | - | $136.54 M(-22.1%) |
Dec 2006 | $175.38 M(+52.7%) | $175.38 M(-30.8%) |
Sept 2006 | - | $253.50 M(+31.3%) |
June 2006 | - | $193.07 M(+90.3%) |
Mar 2006 | - | $101.46 M(-11.6%) |
Dec 2005 | $114.82 M(-44.7%) | $114.82 M(-31.5%) |
Sept 2005 | - | $167.71 M(+0.7%) |
June 2005 | - | $166.55 M(-21.8%) |
Mar 2005 | - | $213.06 M(+2.6%) |
Dec 2004 | $207.57 M(+13.8%) | $207.57 M(-20.0%) |
Sept 2004 | - | $259.41 M(+15.7%) |
June 2004 | - | $224.15 M(+18.1%) |
Mar 2004 | - | $189.75 M(+4.1%) |
Dec 2003 | $182.33 M(+48.8%) | $182.33 M(+11.0%) |
Sept 2003 | - | $164.32 M(+13.8%) |
June 2003 | - | $144.34 M(+26.6%) |
Mar 2003 | - | $114.01 M(-6.9%) |
Dec 2002 | $122.51 M(+110.2%) | $122.51 M(+9.0%) |
Sept 2002 | - | $112.39 M(+32.7%) |
June 2002 | - | $84.71 M(-37.4%) |
Mar 2002 | - | $135.40 M(+132.4%) |
Dec 2001 | $58.27 M(+75.9%) | $58.27 M(-25.6%) |
Sept 2001 | - | $78.30 M(+175.6%) |
June 2001 | - | $28.42 M(-60.8%) |
Mar 2001 | - | $72.40 M(+118.5%) |
Dec 2000 | $33.13 M(+120.7%) | $33.13 M(+18.3%) |
Sept 2000 | - | $28.01 M(+47.5%) |
June 2000 | - | $18.99 M(+2.9%) |
Mar 2000 | - | $18.46 M |
Dec 1999 | $15.01 M(-39.5%) | - |
Dec 1998 | $24.81 M | - |
FAQ
- What is Charles River Laboratories International annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Charles River Laboratories International?
- What is Charles River Laboratories International annual cash & cash equivalents year-on-year change?
- What is Charles River Laboratories International quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Charles River Laboratories International?
- What is Charles River Laboratories International quarterly cash and cash equivalents year-on-year change?
What is Charles River Laboratories International annual cash & cash equivalents?
The current annual cash & cash equivalents of CRL is $276.77 M
What is the all time high annual cash & cash equivalents for Charles River Laboratories International?
Charles River Laboratories International all-time high annual cash & cash equivalents is $276.77 M
What is Charles River Laboratories International annual cash & cash equivalents year-on-year change?
Over the past year, CRL annual cash & cash equivalents has changed by +$42.86 M (+18.32%)
What is Charles River Laboratories International quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CRL is $210.17 M
What is the all time high quarterly cash and cash equivalents for Charles River Laboratories International?
Charles River Laboratories International all-time high quarterly cash and cash equivalents is $465.41 M
What is Charles River Laboratories International quarterly cash and cash equivalents year-on-year change?
Over the past year, CRL quarterly cash and cash equivalents has changed by -$66.60 M (-24.06%)